Please assess the completion status of the following clinical trial:

Trial Title: DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent prior to any study specific procedures~* Male or female, aged ≥18 years~* Documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV), which has been present for at least 8 weeks~* LVEF≤40%~* Elevated NT-proBNP levels~* Patients should receive background standard of care as described below: All HFrEF patients should be treated according to locally recognised guidelines on standard of care treatment with both drugs and devices, as appropriate. Guideline-recommended medications should be used at recommended doses unless contraindicated or not tolerated. Therapy should have been individually optimised and stable for ≥4 weeks (this does not apply to diuretics) before visit 1 and include (unless contraindicated or not tolerated):~  * an ACE inhibitor, or ARB or sacubitril/valsartan and~ * a beta-blocker and~ * if considered appropriate by the patient's treating physician; a mineral corticoid receptor antagonist~* 6MWD≥100 metres and ≤425 metres at enrolment and randomization.~Exclusion Criteria:~* Presence of any condition that precludes exercise testing~* Participation in a structured exercise training programme in the 1 month prior to screening or planned to start during the trial~* Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor~* Type 1 diabetes mellitus~* eGFR \<25 mL/min/1.73 m2 (CKD-EPI formula) at enrolment, unstable or rapidly progressing renal disease at time of randomisation~* Systolic BP \<95 mmHg on 2 consecutive measurements~* Systolic BP ≥160 mmHg if not on treatment with ≥3 blood pressure lowering medications or ≥180 mmHg irrespective of treatments, on 2 consecutive measurements~* Current acute decompensated HF or hospitalisation due to decompensated HF \<4 weeks prior to enrolment~* MI, unstable angina, coronary revascularization ablation of atrial flutter/fibrillation, valve repair/replacement, implantation of a cardiac resynchronization therapy device within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization.~* Stroke or transient ischemic attack within 12 weeks prior to enrolment.~* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD.~* Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization~* HF due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 150 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Green, diamond shaped, film coated tablets placebo administered orally, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).